Reserpine hydrochlorideCAS# 16994-56-2 |
- LDN-193189
Catalog No.:BCC3687
CAS No.:1062368-24-4
- LDN193189 Hydrochloride
Catalog No.:BCC1695
CAS No.:1062368-62-0
- LY364947
Catalog No.:BCC5085
CAS No.:396129-53-6
- Pirfenidone
Catalog No.:BCC5086
CAS No.:53179-13-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 16994-56-2 | SDF | Download SDF |
| PubChem ID | 3084265 | Appearance | Powder |
| Formula | C33H41ClN2O9 | M.Wt | 645.14 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 12.66 mg/mL (19.62 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | methyl (15R,18S,20R)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate;hydrochloride | ||
| SMILES | COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC.Cl | ||
| Standard InChIKey | ZYWIWGUMKCZKOO-OSYYGSGGSA-N | ||
| Standard InChI | InChI=1S/C33H40N2O9.ClH/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19;/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3;1H/t18-,22+,24?,27?,28?,31+;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).In Vitro:Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2). Reserpine hydrochloride displays a significant on the density of dopamine D1 receptors (F2,12=8.81, p<0.01) in the rat striatum. The affinity (Kd) for the dopamine D1 and D2 receptors during withdrawal from acute and chronic administration of reserpine is not change[1]. IC50 values of 43.9 and 54.9 μM are obtained after 1 day of treatment with Reserpine hydrochloride in JB6 P+ and HepG2-C8 cells, respectively. Reserpine hydrochloride induces luciferase activity in a dose-dependent manner at concentrations ranging from 5 to 50 μM, and no significant induction is observed at concentrations lower than 5 μM. Results demonstrate that Reserpine hydrochloride (2.5 to 10 μM) also increases the protein expression of Nrf2, HO-1, and NQO1. Reserpine hydrochloride at concentrations of 2.5 to 10 μM decreases the mRNA expression of DNMT1, DNMT3a, and DNMT3b in a concentration-dependent manner in JB6 P+ cells after 7 days of treatment. Reserpine hydrochloride at 10 μM generates a significant difference for DNMT3a expression (p<0.05)[2].In Vivo:Withdrawal (48 h) from chronic (14-day) but not acute Reserpine hydrochloride administration in a dose of 0.2 mg/kg i.p. produces a significant reduction of the immobility time (F2,18=3.68, p<0.05), but increases the climbing time (F2,18=4.48, p<0.02), and does not change the swimming time (F2,18=1.78; NS) in the forced swim test (FST) in rats[1]. Reserpine hydrochloride at a dose of 5 mg/kg body weight produces significant increase in the urinary excretion profile of vanillylmandelic acid (VMA) compare to control animals. The amount of 5-hydroxyindoleacetic acid (5-HIAA) excreted in animals treated with Reserpine is found to be more than in the control. Dose dependent hypotension is observed with Reserpine hydrochloride. Reserpine hydrochloride at doses of 0.5, 1, 5, 10 and 15 μg/kg produce significant (p<0.01) reduction in blood pressure compare to control[3]. References: | |||||
Reserpine hydrochloride Dilution Calculator
Reserpine hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5501 mL | 7.7503 mL | 15.5005 mL | 31.001 mL | 38.7513 mL |
| 5 mM | 0.31 mL | 1.5501 mL | 3.1001 mL | 6.2002 mL | 7.7503 mL |
| 10 mM | 0.155 mL | 0.775 mL | 1.5501 mL | 3.1001 mL | 3.8751 mL |
| 50 mM | 0.031 mL | 0.155 mL | 0.31 mL | 0.62 mL | 0.775 mL |
| 100 mM | 0.0155 mL | 0.0775 mL | 0.155 mL | 0.31 mL | 0.3875 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Reserpine hydrochloride (Serpalan) is an indole alkaloid antipsychotic and antihypertensive drug that irreversibly blocks the vesicular monoamine transporter (VMAT).
- LY 333531 hydrochloride
Catalog No.:BCC7969
CAS No.:169939-93-9
- Iso-cuparenal
Catalog No.:BCN7350
CAS No.:16982-01-7
- Mesuol
Catalog No.:BCN6583
CAS No.:16981-20-7
- Dibutyryl-cAMP, sodium salt
Catalog No.:BCC8079
CAS No.:16980-89-5
- Angelol K
Catalog No.:BCN8142
CAS No.:169736-93-0
- Ro 60-0175 fumarate
Catalog No.:BCC7196
CAS No.:169675-09-6
- Z-Thr(tBu)-OH.DCHA
Catalog No.:BCC2565
CAS No.:16966-07-7
- Isodonal
Catalog No.:BCN3390
CAS No.:16964-56-0
- Trichosanatine
Catalog No.:BCN1818
CAS No.:169626-16-8
- Odoratone
Catalog No.:BCN1105
CAS No.:16962-90-6
- Celecoxib
Catalog No.:BCC1099
CAS No.:169590-42-5
- Deracoxib
Catalog No.:BCC4108
CAS No.:169590-41-4
- Bufarenogin
Catalog No.:BCN2297
CAS No.:17008-65-0
- Pseudobufarenogin
Catalog No.:BCN8234
CAS No.:17008-69-4
- Alvimopan dihydrate
Catalog No.:BCC1348
CAS No.:170098-38-1
- Curcolone
Catalog No.:BCN3559
CAS No.:17015-43-9
- Nepicastat (SYN-117) HCl
Catalog No.:BCC2286
CAS No.:170151-24-3
- 11-Keto-beta-boswellic acid
Catalog No.:BCN2298
CAS No.:17019-92-0
- Bauerenol acetate
Catalog No.:BCN1106
CAS No.:17020-04-1
- 24-Methylenecycloartane-3beta,26-diol
Catalog No.:BCN1530
CAS No.:17020-27-8
- CD 2314
Catalog No.:BCC6071
CAS No.:170355-37-0
- CD 2665
Catalog No.:BCC7778
CAS No.:170355-78-9
- Enzastaurin (LY317615)
Catalog No.:BCC1100
CAS No.:170364-57-5
- 4-(6-Methyl-4-oxohept-5-en-2-yl)cyclohex-2-en-1-one
Catalog No.:BCN7528
CAS No.:170380-68-4
Protection by procaine hydrochloride against reserpine-induced acute gastric mucosal injury in the rat: implications for stress-induced injury.[Pubmed:3171945]
J Pharm Sci. 1988 Jul;77(7):582-5.
This study investigated whether oral procaine (1 mL of 5% solution) affords protection against reserpine-induced (5 mg/kg, ip) acute gastric mucosal injury in the rat. After 6 h, all rats in the reserpine-alone group developed mucosal injury confined to the glandular stomach (40.1 +/- 5.2 mm2, mean +/- SEM), and neither atropine (5 mg/kg, ip) or cimetidine (40 mg/kg ip) influenced this injury (38 +/- 4 and 40.5 +/- 4.6 mm2, respectively). Similarly, celiac ganglionectomy, to interrupt autonomic sympathetic delivery to the stomach, had no effect on the reserpine-induced injury (42 +/- 6 versus 40.1 +/- 5.2 mm2). Dose-dependent protection against the reserpine injury was produced by the alpha-adrenoceptor blocking drug phenoxybenzamine or phentolamine: a complete protection was noted with the 15-mg/kg dose. Vagotomy or procain completely protected the rat stomach against the reserpine injury. The data suggest that reserpine produces vagal adrenoceptor delivery to the rat stomach, resulting in mucosal injury, and that oral procaine blocks this delivery, thus achieving protection against injury development by a vagotomy action. The knowledge that the reserpine injury is a stress-induced injury indicates that oral procaine protects the rat stomach against stress-induced acute gastric mucosal injury.
The L-DOPA-sparing effect of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in reserpine-pretreated rats.[Pubmed:12527038]
Life Sci. 2003 Feb 7;72(12):1413-9.
R-(-)-1-(Benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP], a highly potent enhancer of impulse propagation-mediated release of catecholamines and serotonin in the brain, and significantly increased the locomotor activity of normal rats at the doses of 0.3 and 1 mg/kg s.c. (P < 0.05), while L-DOPA (200 and 400 mg/kg i.p.) had no significant effect. The locomotor activity of rats simultaneously administered L-DOPA and (-)-BPAP was significantly higher than with (-)-BPAP alone (P < 0.05). In rats pretreated with reserpine (1 mg/kg i.v.), the hypolocomotion was significantly reversed by 400 mg/kg i.p. L-DOPA, or 1 or 3 mg/kg s.c. (-)-BPAP (P < 0.05). Furthermore, the combined administration of subthreshold doses of 200 mg/kg i.p. L-DOPA and 0.3 mg/kg s.c. (-)-BPAP highly potentiated the locomotor activity in the reserpine-pretreated rats. However, (-)-BPAP failed to reverse the hypolocomotion in rats pretreated with reserpine + alpha-methyl-DL-p-tyrosine. Thus, (-)-BPAP was demonstrated to possess the L-DOPA-sparing effect in normal and reserpine-pretreated rats.
Simultaneous Estimation of Hydrochlorothiazide, Hydralazine Hydrochloride, and Reserpine Using PCA, NAS, and NAS-PCA.[Pubmed:26839841]
Sci Pharm. 2015 Jun 22;83(4):599-610.
In this study, new and feasible UV-visible spectrophotometric and multivariate spectrophotometric methods were described for the simultaneous determination of hydrochlorothiazide (HCTZ), hydralazine hydrochloride (H.HCl), and reserpine (RES) in combined pharmaceutical tablets. Methanol was used as a solvent for analysis and the whole UV region was scanned from 200-400 nm. The resolution was obtained by using multivariate methods such as the net analyte signal method (NAS), principal component analysis (PCA), and net analyte signal-principal component analysis (NAS-PCA) applied to the UV spectra of the mixture. The results obtained from all of the three methods were compared. NAS-PCA showed a lot of resolved data as compared to NAS and PCA. Thus, the NAS-PCA technique is a combination of NAS and PCA methods which is advantageous to obtain the information from overlapping results.
